Cancer Research UK Purchases Fluidigm Genotyping System | GenomeWeb

NEW YORK (GenomeWeb News) — Fluidigm said today that Cancer Research UK's Centre for Genetic Epidemiology, University of Cambridge, will use its EP1 system to conduct cancer research and disease-association studies.

The center will use the integrated fluidic circuit-based high throughput genotyping system to identify and verify genetic variants that underlie susceptibility to various cancers, including colorectal, prostate, melanoma, breast, and ovarian. The research will take place at the University's Strangeways Research Laboratory.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.